Verastem (NASDAQ:VSTM) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Thursday, BidAskClub reports.

VSTM has been the subject of a number of other research reports. Cantor Fitzgerald raised their price objective on Verastem from $3.00 to $6.00 and gave the company an “overweight” rating in a research report on Tuesday, March 3rd. HC Wainwright raised their price objective on Verastem from $2.50 to $2.75 and gave the company a “buy” rating in a research report on Monday, March 16th. ValuEngine upgraded Verastem from a “hold” rating to a “buy” rating in a research report on Thursday, March 12th. Finally, Zacks Investment Research lowered Verastem from a “buy” rating to a “hold” rating in a research report on Wednesday, January 1st. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Verastem presently has a consensus rating of “Buy” and a consensus price target of $5.95.

NASDAQ:VSTM traded up $0.21 on Thursday, reaching $2.49. 1,495,112 shares of the company’s stock traded hands, compared to its average volume of 3,342,669. The company has a quick ratio of 2.74, a current ratio of 2.84 and a debt-to-equity ratio of 14.93. The stock has a 50-day simple moving average of $2.25 and a 200-day simple moving average of $1.57. The firm has a market cap of $361.61 million, a PE ratio of -1.24 and a beta of 2.04. Verastem has a 12 month low of $0.83 and a 12 month high of $3.49.

Verastem (NASDAQ:VSTM) last posted its quarterly earnings results on Wednesday, March 11th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.05). The business had revenue of $3.62 million for the quarter, compared to the consensus estimate of $5.11 million. Verastem had a negative net margin of 854.77% and a negative return on equity of 339.98%. On average, equities analysts anticipate that Verastem will post -0.58 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Creative Planning boosted its position in shares of Verastem by 26.9% during the fourth quarter. Creative Planning now owns 117,547 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 24,950 shares during the period. Aries Wealth Management raised its stake in shares of Verastem by 100.0% during the fourth quarter. Aries Wealth Management now owns 20,003 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10,000 shares in the last quarter. Samalin Investment Counsel LLC bought a new stake in shares of Verastem during the fourth quarter valued at approximately $118,000. Middleton & Co Inc MA bought a new stake in shares of Verastem during the fourth quarter valued at approximately $40,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Verastem during the fourth quarter valued at approximately $126,000. Institutional investors own 21.23% of the company’s stock.

About Verastem

Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.

Featured Story: Dow Jones Industrial Average (DJIA)

Analyst Recommendations for Verastem (NASDAQ:VSTM)

Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.